Company Overview - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to modulate the expression of disease-causing genes [3] Upcoming Presentation - Management will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website and archived for at least 30 days [2] Product Development - The company is advancing clinical-stage programs including DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy [3] - Additional programs are in development for myotonic dystrophy type-1 and Huntington's disease, with ongoing discovery efforts for multiple genomic medicines [3]